Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 1386

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1A
Chunk 1386
---
 legal and other expenses in order to comply with requirements of the SEC,
and the Nasdaq Capital Market, including requirements under Section 404 and other provisions of the Sarbanes-Oxley Act. Pursuant to Section
404, we are required to furnish a report by our management on our internal control over financial reporting. However, so long as we remain
a smaller reporting company, we will not be required to include an attestation report on internal control over financial reporting issued
by our independent registered public accounting firm. The process to document and evaluate our internal control over financial reporting
to achieve compliance with Section 404 within the prescribed period is both costly and challenging. If we fail to maintain the adequacy
of our internal control over financial reporting as such standards are modified, supplemented or amended from time to time, we may not
be able to ensure that we can conclude on an ongoing basis that we have effective internal control over financial reporting in accordance
with Section 404 of the Sarbanes-Oxley Act of 2002 and the related rules and regulations of the SEC. If we cannot in the future favorably
assess the effectiveness of our internal control over financial reporting, investor confidence in the reliability of our financial reports
may be adversely affected, which could have a material adverse effect on our share price.

If
the Domestication Merger (defined below), taken together with the Merger (defined below), fails to qualify as a Section 351(a) Exchange,
former U.S. holders of Intec Pharma (“Intec Israel”) ordinary shares may recognize taxable gain as a result of the Domestication
Merger.

On
July 27, 2021, Intec Israel, Indaptus Therapeutics, Inc. and Domestication Merger Sub Ltd., an Israeli company and a wholly owned subsidiary
of Indaptus, completed a domestication merger (the “Domestication Merger”), pursuant to the terms and conditions of an Agreement
and Plan of Merger and Reorganization, dated April 27, 2021, whereby Domestication Merger Sub Ltd. merged with and into Intec Israel,
with Intec Israel being the surviving entity and a wholly-owned subsidiary of Indaptus Therapeutics, Inc. On August 3, 2021, Indaptus
Therapeutics, Inc. completed its merger with Decoy, pursuant to an Agreement and Plan of Merger and Reorganization (the “Merger
Agreement”), dated March 15, 2021,